NICE Rejects Donanemab: Treatment Cost-Effectiveness

By Staff Writer

June 19, 2025

How cost-effective is donanemab as an Alzheimer’s treatment, and why did NICE reject its routine use on the NHS?

In June 2025, NICE concluded that the donanemab Alzheimer’s treatment cost-effectiveness does not justify routine NHS adoption for adults with mild cognitive impairment or mild dementia due to Alzheimer’s disease. Despite offering some slowdown in cognitive decline, the modest clinical benefits of donanemab were outweighed by high costs and persistent uncertainties about long-term impact. This aligns with the NHS’s focus on evidence-based, sustainable care and highlights the rigorous cost-effectiveness standards facing new Alzheimer’s therapies.

Key Findings: Donanemab’s Clinical Benefits and Economic Challenges

  • Insufficient Clinical Improvement:
    Donanemab slowed cognitive and functional decline versus placebo in major trials (22–32% reduction in progression over 18 months), but the total benefit was less than what the wider research community regards as clinically meaningful.
  • Cost-Effectiveness Concerns:
    NICE’s health economic modelling revealed that the most plausible incremental cost-effectiveness ratio (ICER) for donanemab is about £69,000 per QALY gained, well above the £20,000 threshold typically used by the NHS.
  • Substantial Uncertainty:
    Key variables—such as the durability of donanemab’s effect, mortality risk changes, and impacts on patient and caregiver quality of life—introduced significant uncertainty into cost-effectiveness analyses.
  • Implementation Barriers:
    Adopting donanemab would require major changes to NHS infrastructure: expanded early diagnosis, specialist amyloid/genetic testing, frequent infusions, and close monitoring for side effects—all at considerable cost.
  • No Managed Access:
    NICE found that even with further data collection or restricted access, donanemab’s cost-effectiveness is unlikely to meet NHS criteria. Learn more about these considerations in NICE’s detailed analysis of Alzheimer’s treatments.

Background: Alzheimer’s Disease Treatments and Innovation

Alzheimer’s disease remains the most prevalent dementia in the UK, with current treatments largely limited to symptom management (e.g., acetylcholinesterase inhibitors like donepezil).
Donanemab represents a new category: monoclonal antibodies targeting amyloid beta, designed to slow disease progression rather than just alleviate symptoms. However, a parallel review also found lecanemab failed to meet NICE’s standards for cost-effectiveness.

Evidence and Expert Evaluation

  • TRAILBLAZER-ALZ 2 Clinical Trial:
    Data showed statistically significant—but modest—improvements in outcomes such as the integrated Alzheimer Disease Rating Scale (iADRS). The absolute gains were about half those considered truly meaningful to patients.
  • Global Regulatory Perspective:
    While the FDA and EMA have granted conditional approvals for similar drugs, they acknowledge unresolved questions about long-term benefits and real-world value.

Economic Modeling

NICE rigorously assessed donanemab Alzheimer’s treatment cost-effectiveness using comprehensive economic modeling. Key focal points included:

  • Real-world costs associated with NHS implementation.
  • Impacts on both patient and caregiver quality of life (QOL), despite QOL measurement challenges in dementia care.
  • Transparency in assumptions about mortality, disease stage progression, and treatment durability.

These factors reinforce NICE’s prioritization of robust evidence and trusted methodologies in determining NHS coverage.

Health Economics and Policy Implications

The donanemab decision has broad consequences for future Alzheimer’s disease therapy assessments:

  1. Cost-Effectiveness Is Crucial:
    Only treatments delivering substantial, clearly demonstrable value relative to their cost will be considered for NHS adoption.
  2. Standard-Setting for Future Drugs:
    Other disease-modifying Alzheimer’s drugs must address clinical and economic uncertainties, and show improvement in both efficacy and long-term affordability.
  3. Service Delivery Equity:
    Complex eligibility and diagnostic requirements may risk widening existing disparities in dementia care, making attention to health equity a necessary part of future decision-making.
  4. Stimulus for Innovation:
    Drug developers must generate higher-quality real-world data and prioritize outcomes relevant to both patients and carers, as cost-effectiveness continues to drive NHS access policy.

Structured Summary Table: Donanemab at a Glance

Factor Donanemab Outcome
Clinical Benefit 22–32% slower decline in key markers, modest vs. meaningful threshold
ICER (Cost/QALY) ~£69,000 per QALY (vs. NHS threshold up to £20,000)
Primary Evidence TRAILBLAZER-ALZ 2 trial, supported by phase 1/2 studies
Care Delivery Changes Requires early diagnosis, specialist testing, frequent infusions
NICE Final Guidance Not recommended for routine or managed access in the NHS

Frequently Asked Questions (FAQ)

1. What is the main reason NICE rejected donanemab for NHS use?
The primary reason was that donanemab Alzheimer’s treatment cost-effectiveness remains far outside accepted thresholds, given only modest clinical benefits.

2. Did donanemab actually help patients with early Alzheimer’s?
Yes, there was a statistically significant slowing of cognitive decline, but the degree of improvement was not large enough to be considered meaningful for most patients.

3. How does this affect future Alzheimer’s drug approvals in the UK?
Future therapies will need to offer greater clinical benefit, address long-term uncertainties, and demonstrate clear, cost-effective value to meet NHS acceptance criteria.

Conclusion and Next Steps

The NICE assessment of the donanemab Alzheimer’s treatment cost-effectiveness sets a high bar for future innovations in dementia care. While the search for disease-modifying Alzheimer’s therapies continues, new drugs must demonstrate meaningful patient benefits, robust real-world impact, and sustainable cost profiles to meet NHS standards. Explore more about the evolving landscape of Alzheimer’s treatments and cost-effectiveness in NICE’s detailed guidance.

Reference url

Recent Posts

implantable glucose device
         

T1 Diabetes Care with an Implantable Glucose Device

🚀 Are we on the brink of a diabetes breakthrough?

A newly developed implantable glucose device from MIT could revolutionize diabetes management, providing an autonomous solution to prevent life-threatening hypoglycemic episodes. This innovative device combines continuous glucose monitoring with responsive hormone delivery, potentially transforming patient care by reducing the need for constant oversight.

Curious about how this technology could reshape diabetes outcomes and healthcare economics? Dive into the full article for a closer look!

#SyenzaNews #HealthTech #HealthEconomics #Innovation

federated learning governance
      

Federated Learning Governance in Healthcare: A Framework for Ethical and Effective Implementation

🔍 Have you considered how federated learning governance can revolutionize healthcare data collaboration?

In our latest article, we explore the critical principles of federated learning governance, emphasizing its role in managing decentralized health data while protecting patient privacy and improving research quality. Learn about the actionable strategies healthcare organizations can implement to navigate the unique challenges that come with this innovative approach.

Dive deeper into the world of federated learning in healthcare and unlock its potential for ethical and effective data use!

#SyenzaNews #AIinHealthcare #DigitalHealth

Cecolin 9 HPV vaccine
        

Cecolin 9 HPV Vaccine: A Game Changer for Cervical Cancer Prevention in China

🌍 Did you know that China has just achieved a historic milestone in the fight against cervical cancer?

The approval of the Cecolin 9 HPV vaccine, the first domestically developed 9-valent HPV vaccine, marks a transformative moment for public health, enhancing access and affordability across the nation. This development not only meets global health goals but also reshapes the landscape of cervical cancer prevention in China.

Curious to learn how this advancement is set to impact vaccination efforts and healthcare economics? Dive into the full article for deeper insights!

#SyenzaNews #globalhealth #HealthEconomics

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER

© 2025 Syenza™. All rights reserved.